Phase I Study Evaluating Oral Azacitidine as Potential Treatment for Patients With Acute Myeloid Leukemia Presented at the American Society of Hematology Meeting  
12/12/2011 7:46:15 AM

BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ:CELG), announced results from a multi-center Phase I study that explored multiple dosing schedules of oral azacitidine in 23 patients with acute myeloid leukemia (AML), myelodysplastic syndromes or chronic myelomonocytic leukemia (CMML) who were not candidates for other therapies or who had failed previous regimens. These findings were presented during the 53rd Annual Meeting of the American Society of Hematology in San Diego, CA.